

CURRICULUM VITAE

CHARLES E. EIRIKSSON, JR., MD, FACC

Main Location:

300 E. Jefferson, Suite 101 – Boise, ID 83712 – (208) 322-1680 – FAX (208) 336-4035

Additional Offices:

520 S. Eagle Road, Suite 3104 – Meridian, ID 83642 – (208) 322-1680 – FAX (208) 884-3096

315 E. Elm Street, Suite 350 – Caldwell, ID 83605 – (208) 454-6363 – FAX (208) 454-3512

1500 W. Shoreline – Boise, ID 83702 – (208) 322-1680 – FAX (208) 322-1695

PO Box 110 – Boise, ID 83701-0110

CURRENT POSITION

Oct 2007- Present

Interventional Cardiologist
St. Luke's Idaho Cardiology Associates
PO Box 110
Boise, Id 83701-0110

1994 – Oct 2007

Interventional Cardiologist
Idaho Cardiology Associates, P.A.,
300 East Jefferson Street, Suite 201
Boise, ID 83712
Phone: (208) 336-4141

Idaho Cardiology Associates, PA
6140 W. Curtisian Ave. Ste.200
Boise, ID 83704
Phone: (208) 322-1680

2005- Present

President- Idaho Cardiology Associates, P.A.

EDUCATION

1969 - 1973

Doctor of Medicine
University of Washington School of Medicine
Seattle, Washington

1965 - 1969

Bachelor of Arts (Summa cum laude)
Dartmouth College
Hanover, NH


POSTGRADUATE EDUCATION

1973 - 1974

Medicine Internship
University of Utah Affiliated Hospitals
Salt Lake City, UT

1974 - 1976

Residency in Internal Medicine
University of Utah Affiliated Hospitals

Signature: 

Date: 7/27/09

Revised 07-15-09

Salt Lake City, UT

1976 – 1978

Cardiology Fellowship, Martinez VA Hospital
UC Davis School of Medicine
Martinez, CA

MEDICAL LICENSE

Current State of Idaho, No. M-4580
Inactive State of Washington, No. 0015583

HOSPITAL AFFILIATIONS

St. Luke's Regional Medical Center, Boise, Idaho
Veteran's Administration Medical Center, Boise, Idaho

SPECIALTY BOARDS

2000 Fellow, American College of Cardiology
June 1976 Board Certified in Internal Medicine
June 1999-2009 Board Certified in Interventional Cardiology, (#54256)

PAST CLINICAL EXPERIENCE


1983 - 1993 Cardiologist
Boise Heart Clinic, P.A.,
287 West Jefferson St., Boise, Idaho

ACADEMIC POSITIONS

1985 - Present Associate Clinical Professor in Medicine
University of Washington School of Medicine, Seattle, WA
1982 - 1985 Assistant Professor in Medicine
University of Washington School of Medicine, Seattle, WA
1979 - 1982 Instructor of Medicine
University of Washington School of Medicine, Seattle, WA

MEMBERSHIPS

1993-1996 Chairman, Department of Medicine

Signature:  _____

Date: 7/27/09

1992-1995
1985-1993
1988
1992-1995
1985- 1990

Member, Board of Directors, St. Luke's Regional Medical Center
Chairman P&T Committee, St. Luke's Regional Medical Center
President, Ada County Medical Society
Idaho Governor, American College of Cardiology
National Faculty, Advanced Cardiac Life Support

1985
1983-Present
1983-Present
1982-1988
1981-Present
1981-Present
1980-1982

1980-1986
1979-Present

President American Heart Association of Idaho
Member, Ada County Medical Society
Member, Idaho Medical Association
Chairman, Emergency Cardiac Care Committee
Fellow, Council on Clinical Cardiology
Fellow, American College of Cardiology
Medical Supervisory Committee,
Ada County Emergency Medical Service
Board of Directors, AHA of Idaho
Member, American Heart Association

HONORS & AWARDS

Phi Beta Kappa
Alpha Omega Alpha

PUBLICATIONS

Papers:

Vestal RE, Eiriksson CE, Jr., Musser B, Ozaki LK, Halter JB: Effect of Intravenous Aminophylline on Plasma Levels of Catecholamines and Related Cardiovascular and Metabolic Responses in Man. *Circulation* 67:162-171, 1983.

Eiriksson CE, Jr., Brogden RN: Lorcainide. A Preliminary Review of its Pharmacodynamic Properties and Therapeutic Efficacy. *Drugs* 27:279-300, 1984.

Eiriksson CE, Jr., Writer SL, Vestal RE: Theophylline-Induced Alterations in Cardiac Electrophysiology in Patients with Chronic Obstructive Pulmonary Disease. *American Review of Respiratory Disease* 135:322-326, 1987.

Dattilo G, Eiriksson CE, Jr., Vestal RE: Increased Ventricular Response Rate During Exercise in Patients with Atrial Fibrillation Treated with Theophylline. *Arch Intern Med* 152:797-803, 1992.

Abstracts:

Vestal RE, Eiriksson CE, Jr., Musser B, Ozaki LK, Halter JB: Catecholamine and Cardiovascular Response to Acute Theophylline Infusion. *Clin Res* 29:23A, 1981.

Signature: _____



Date: 7/27/09

Vestal RE, Eiriksson CE, Jr., Musser B, Ozaki LK, Halter JB:
Sympathetic Nervous System Stimulation: Possible Mechanism for
Cardiovascular and Metabolic Effects of Theophylline in Man.
Clin Res 29:279A, 1981.

Eiriksson, CE, Jr., Writer SL, Vestal RE: Cardiac Electrophysiologic Effects of
Theophylline. Clin Res 32:70A, 1987.

Eiriksson CE, Jr.: Cardiac Drugs in the Elderly, in Drug Therapy in the Elderly,
edited by Vestal, RE. Auckland, New Zealand, Adis Health Science Press: p61-
76, 1984.

Cusack, BJ, Olson, RD, Eiriksson, CE: Chronic heart failure, in Drug Therapy in
Old Age, edited by George, CF, Woodhouse, KW, Denham MJ, MacLennan, WJ.
West Sussex, England, John Wiley & Sons Ltd.: p125-148, 1998

RESEARCH ACTIVITIES

Sub-Investigator:

Protocol CVAL489 0108 VALIANT Clinical Trial (Novartis, 1998)

Sub-Investigator:

Prevention of Sudden Cardiac death Heart Failure Trial (SCDHeFT) (National
Heart, dFLung and Blood Institute and Medtronic, Inc. 1998)

Sub-Investigator:

Protocol AMISTAD II A Randomized Clinical Trial (Medco Research, Inc.,
1998)

Sub-Investigator:

Protocol MAGIC Clinical Trial (New England Research Institutes, 1998)

Sub-Investigator:

Phase III Protocol BRL009952AA/004 PRESTO Clinical Trial (SmithKline
Beecham, 1999)

Sub-Investigator:

Protocol SIMVASTATIN Clinical Trial (Merck, 1999)

Sub-Investigator:

Protocol ADEPT Clinical Trial (Medtronic, 1999)

Sub-Investigator:

Signature:  _____

Date: 7/27/09

Protocol Acute Evaluation of Atrial Autocapture Compatabilty Using Affinity DR Device (St. Jude Medical, 1998)

Sub-Investigator:

Protocol Autocapture Pacing Systems with Competitive Leads (St. Jude Medical, 1999)

Sub-Investigator:

Protocol 99-24S Medtronic Model 7250 Arrhythmia Management Device VT/VF + AF (Medtronic, 1999)

Sub-Investigator:

Protocol SYNERGY Clinical Trial (Aventis, 2001)

Sub-Investigator:

HAT- Registry The purpose of the study is to determine all cause mortality comparing Home Automated External Defibrillators versus Lay Person CPR in Sudden Cardiac Arrest. (Home AED Trial (HAT) NIH funded, 2003-2006)

Sub-Investigator:

A Phase III, Multi-center, double-blind, parallel group, placebo-controlled trial. ARISE-Aggressive Reduction of Inflammation Stops Events. Reduction of vascular inflammation and coronary atherosclerosis with AGI-XXXX, a V-Protectant, reduces cardiovascular events in subjects with Coronary Artery Disease. (AtheroGenics, Inc. 2003-2006)

Sub-Investigator:

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Impact of Subcutaneous (SC) Darbepoetin Alfa Treatment on Exercise Tolerance in Subjects with Symptomatic Congestive Heart Failure (CHF) and Anemia. (STAMINA-HeFT Study) by Otsuka Maryland Research Institute, 2003

Sub-Investigator:

A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety and Efficacy of BO-653 in the Prevention of Post-Angioplasty Restenosis in Stented Lesions (PREVAIL Study) Chugai Pharmaceuticals, 2002

Sub-Investigator:

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to evaluate the long term efficiency and safety of Oral ##### Tablets in subjects hospitalized with worsening Congestive Heart Failure. (Otsuka Maryland Research Institute, Inc. EVEREST Study 2003-2006)

Signature: _____



Date: 7/27/09

Sub-Investigator:

ARRIVE 2- Registry A registry of patients being treated with the TAXUS™ Express²™ Paclitaxel-Eluting Coronary Stent System. The purpose of the registry is to collect additional safety data on the TAXUS Stent system.(Boston Scientific, 2004-2006)

Sub-Investigator:

DISCOVER Registry Prospective, multi-center, observational study. (Cordis Corp.,2005)

Sub-Investigator:

A Phase III, Multi-center, risk-stratified, randomized, double-blind, double-dummy study drug administration, active-controlled (i.e. adenosine), complete two-arm crossover study with a reference third arm. Vasodilator Induced Stress In Concordance with Adenosine (VISION-305) (King Pharmaceuticals Research and Development, Inc. 2005-2006)

Sub-Investigator:

FLAME, The Filter Wire EZ System Used in the Treatment of an Acute Myocardial Infarction for Embolic Protection. (Boston Scientific Corporation 2004-2006)

Sub-Investigator:

LUNAR 4522US/0001: A Twelve-Week, Randomized, Open-Label, Three-Arm, Parallel Group, Multicenter, Phase IIb Study Comparing the Efficacy and Safety of Rosuvastatin 20mg and 40mg with that of Atorvastatin 80mg in Subjects with Acute Coronary Syndromes.

Sub-Investigator:

Evolve A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Examine the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Standard Therapy with Primary PCI in Patients Diagnosed as Having an ST Elevation Acute Myocardial Infarction

Sub-Investigator:

Double-Blind, Placebo Controlled, Dose Ranging study of the efficiency and safety of SSRXXXXXC 100 or 300mg for the prevention of Ventricular Arrhythmia-Triggered ICD Interventions, ICARIOS (Sanofi-Aventis 2005-2006)

Sub-Investigator:

The WOMEN Study: What is the Optimal Method for Ischemia Evaluation in Women (WOMEN.) A Multi-Center, Prospective, Randomized Study to Establish the Optimal Method for Detection of CAD Risk in Women at an Intermediate-High Pre-Test Likelihood of CAD(Amersham, 2004-2006)

Sub-Investigator:

Signature: _____



Date: 7/27/09

A Pilot Study Examining the Value of Combined Exercise and Adenosine Stress Myocardial Perfusion Imaging as Compared with Adenosine Testing Alone for the Evaluation of Women at Intermediate or High Likelihood for Coronary Heart Disease. Both Exercise and Adenosine Stress Testing, BEAUTY & THE BEAST, (Midwest Heart Foundation, 2005-2006)

Sub-Investigator:

A Phase III, Multi-center, double blind, treatment and follow-up for subjects who have completed ARISE. Follow up Of Clinical Outcomes: The Long-term AGI-XXXX plus Usual Care Study (FOCUS.) (Athero-Genics, Inc 2006)

Sub-Investigator:

A Phase III, Multi-center, randomized, parallel-group, double-blind, double dummy, active-controlled study in subjects with acute coronary syndrome (ACS), who are to undergo percutaneous coronary intervention (PCI). A Comparison of CS-XXX and Clopidogrel. TRITON TIMI-38 (Eli Lilly and Company 2005-2006)

Sub-Investigator:

Prospective, Randomized, Controlled Assessment of Once-Daily Controlled Release COREG CR vs Twice-Daily COREG Immediate Release (IR) On Measures of Compliance and Quality of Life in Patients with Heart Failure and Left Ventricular Systolic Dysfunction (CASPER Study) James E. Udelson, MD 2005-2004

Sub-Investigator:

A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI)
(Proctor and Gamble Pharmaceuticals, 2005-2006)

Sub-Investigator:

Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Oral Tolvaptan on Left Ventricular Dilatation and Function in Patients with Heart Failure and Left Ventricular Systolic Dysfunction. (METEOR Study) Otsuka Maryland Research Institute 2003


Sub-Investigator:

Randomized, double-blind, multicenter clinical trial to compare warfarin and aspirin in patients with heart failure. The primary specific aim is to determine whether warfarin or aspirin is superior for preventing all-cause mortality and stroke combined in patients with ejection fraction (EF) $\leq 35\%$, when balanced against any risk of intracerebral hemorrhage. WARCEF (NIH, 2005-2006)

Sub-Investigator:

Identification of Gene Expression Patterns in Circulating Cells that Predict the Presence of Coronary Artery Disease. PREDICT (2008-2009).

Signature: _____



Date: 7/27/09

Revised 07-15-09

Principle Investigator:

A randomized, double-blind, parallel-group, placebo-controlled, multinational clinical trial to evaluate the efficacy of aliskiren and valsartan versus placebo in lowering levels on NT-proBNP in stabilized patients post acute coronary syndromes. AVANT-GARDE-TIMI-43 (2008-2009).

Sub-Investigator:

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events. (Schering-Plough) 2008-present

Sub-Investigator:

A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome. (Roche/Quintiles) 2008-present.

Principle Investigator:

A Randomized, Partially-Blinded, Multi-Center, Active-Controlled, Dose-Ranging Study Assessing the Safety, Efficacy, and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome. Protocol #REG1-CLIN211 (Regado Biosciences/ Clinsys) 2009-present

Signature: _____



Date: 7/27/09